NCT05073094

Esmolol for Myocardial Protection in Hypertrophic Obstructive Cardiomyopathy

Myocardial Protection With Esmolol in Patients With Hypertrophic Obstructive Cardiomyopathy Undergoing Surgery Under Cardiopulmonary Bypass

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Meshalkin Research Institute of Pathology of Circulation · Network
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Perioperative blockage of beta-adrenoreceptors is widely used in cardiac and non-cardiac surgery to reduce the rate of cardiovascular complications. Several randomized-controlled studies and meta-analysis showed that esmolol reduces the incidence of myocardial ischemia and arrhythmias in cardiac surgery as well as enhances postoperative cardiac performance. No studies assessed the influence of esmolol in patients with hypertrophic obstructive cardiomyopathy undergoing cardiac surgery.

Conditions

• Hypertrophic Obstructive Cardiomyopathy

Interventions

Type	Name	Description
DRUG	Esmolol	Esmolol injected intravenously and added to cardioplegia solution
DRUG	Placebo	Equivalent volume of placebo (saline) as a bolus before aortic cross-clamping and in the cardioplegic solution

Timeline

• Start date: 2021-10-06
• Primary completion: 2023-06-01
• Completion: 2023-07-01
• First posted: 2021-10-11
• Last updated: 2021-10-11

Locations

1 site across 1 country: Russia